Santaris Pharma is set to release new clinical data results from the Phase 2a study of miravirsen, the microRNA-targeted drug designed to treat Hepatitis C virus (HCV) infected patients.

Miravirsen, which is developed using the locked nucleic acid (LNA) drug platform, is an inhibitor of miR-122, a liver specific microRNA required for Hepatitis C virus replication.

The randomised double-blind placebo-controlled ascending multiple-dose Phase 2a study evaluated the safety and tolerability of miravirsen in treatment-naive patients with chronic HCV genotype 1 infection.

The trial demonstrated that miravirsen can be taken as a once-weekly treatment for chronic HCV infection.

The Phase 2a trial showed the drug provided continuous and prolonged anti-viral activity and was well tolerated in patients infected with HCV.

The company plans to present the study findings at the American Association for the Study of Liver Diseases (AASLD) 2011 annual meeting.